SD Pharmaceuticals Launches Licensing Program

SD Pharmaceuticals (SDP) announced that it launched an out-licensing effort on its proprietary nano-emulsion formulations for a variety of intravenous drugs to treat cancer and infectious disease. The formulations are specifically designed to improve the safety profile and remove black box warnings on four currently marketed therapeutically important drugs, which suffer from formulation related adverse effects. The company is actively seeking marketing partners to complete the clinical development of these products and market them.

()a href="http://home.businesswire.com/portal/site/biospace/index.jsp?epi-content=GENERIC&newsId=20050608005223&ndmHsc=v2*A1117623600000*B1118268162000*DgroupByDate*J2*N1000122&newsLang=en&beanID=1229976837&viewID=news_view" target="_blank">BioSpace